Hyponatremia frequently occurs in patients with cancer and is mostly due to a syndrome of inappropriate antidiuresis caused by ectopic secretion of antidiuretic hormone (SIADH). Small cell lung cancer presents with SIADH in approximately 11%-15% of cases. Recently, a new class of drugs, vasopressin V2-receptor antagonists (vaptans), emerged as a promising treatment for SIADH, but efficacy and safety data in cancer patients are lacking. We present a case of SIADH, heralding small cell lung cancer and persisting after apparent complete remission of primary tumor following chemotherapy/radiotherapy, in a patient who underwent long-term treatment with tolvaptan without any serious adverse effects.
Tumori 2015; 101(2): e51 - e53
Article Type: CASE REPORT
AuthorsPaola Bordi, Marcello Tiseo, Sebastiano Buti, Giuseppe Regolisti, Andrea Ardizzoni
- • Accepted on 15/09/2014
- • Available online on 20/02/2015
- • Published online on 28/04/2015
This article is available as full text PDF.
- Bordi, Paola [PubMed] [Google Scholar] 1
- Tiseo, Marcello [PubMed] [Google Scholar] 1, * Corresponding Author (firstname.lastname@example.org)
- Buti, Sebastiano [PubMed] [Google Scholar] 1
- Regolisti, Giuseppe [PubMed] [Google Scholar] 2
- Ardizzoni, Andrea [PubMed] [Google Scholar] 1
Medical Oncology Unit, University Hospital of Parma, Parma - Italy
Pathophysiology of Acute and Chronic Renal Failure Unit, Department of Clinical and Experimental Medicine, University of Parma, University Hospital of Parma, Parma - Italy